Tirzepatide vs Ozempic: Efficacy, Cost, and What to Pick in 2026

Tirzepatide and Ozempic are not the same kind of drug. Ozempic is a brand of semaglutide, a single-receptor GLP-1 agonist. Tirzepatide is a different molecule that activates two receptors at once: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). The dual mechanism is the structural reason behind the larger average weight loss in clinical trials.

There is also a regulatory mismatch most patients do not realize they are comparing across. Ozempic is FDA-approved for type 2 diabetes only. Its widespread use for weight loss is off-label. The semaglutide brand actually approved by the FDA for chronic weight management is Wegovy, the same molecule at a higher maximum dose (2.4 mg per week versus Ozempic’s 2.0 mg). Tirzepatide has the same parallel: Mounjaro is the diabetes brand and Zepbound is the weight-loss brand. We unpack this in the name decoder section below.

This article walks through the comparison the way Harbor’s clinical team walks new members through it: what each drug actually does, what the trials show, how the two compare on side effects and cost in 2026, and how to think about switching from one to the other. We will also note where Ozempic specifically belongs in the picture as opposed to Wegovy, because the answer to “is tirzepatide better than Ozempic” depends partly on what you are actually using Ozempic for.

Before going further, a quick decoder. There are only two molecules across all four names patients commonly compare:

• Semaglutide is the GLP-1 agonist. It is sold under three US brand names: Ozempic (injectable, FDA-approved for type 2 diabetes and cardiovascular risk reduction, max dose 2.0 mg per week), Wegovy (injectable, FDA-approved for chronic weight management, max dose 2.4 mg per week), and Rybelsus (oral, FDA-approved for type 2 diabetes).
• Tirzepatide is the dual GIP and GLP-1 receptor agonist. It is sold under two US brand names: Mounjaro (FDA-approved for type 2 diabetes) and Zepbound (FDA-approved for chronic weight management and, as of 2024, obstructive sleep apnea in adults with obesity), with a maximum dose of 15 mg per week on either brand.

So when patients ask “tirzepatide vs Ozempic,” the clinical comparison they are usually after is tirzepatide versus semaglutide for weight loss. With the caveat that Ozempic, specifically, was never designed to be the maximally effective weight loss form of semaglutide. Wegovy is.

Why the off-label distinction matters

The Ozempic-for-weight-loss phenomenon was driven by an early supply gap. When Wegovy launched in June 2021, semaglutide demand for weight loss outpaced manufacturing capacity. Patients and prescribers turned to Ozempic, which contains the same active ingredient at a lower maximum dose. Cosmetic and celebrity-driven coverage amplified the demand. By 2022, “Ozempic” was being searched as a weight-loss drug an order of magnitude more often than “Wegovy,” and Novo Nordisk’s manufacturing constraints persisted into 2025. As of mid-2026, supply has improved but the brand recognition imbalance has not.

The practical implication is that comparing tirzepatide to Ozempic on weight loss is a slight category mismatch. The closer-on-paper semaglutide for weight loss is Wegovy at its 2.4 mg dose. We include both data points throughout this comparison so the picture is honest.

The cleanest way to compare tirzepatide and semaglutide for weight loss is to look at the registration trials each drug ran to win its FDA indication, and then at the head-to-head data available so far.

STEP-1: semaglutide 2.4 mg (Wegovy dose)

The STEP-1 trial, published in the New England Journal of Medicine in 2021, enrolled 1,961 adults with overweight or obesity and randomized them to semaglutide 2.4 mg weekly or placebo for 68 weeks. The mean body weight reduction was 14.9% on semaglutide compared with 2.4% on placebo. Eighty-six percent of semaglutide participants achieved at least 5% weight loss, and approximately 50% achieved 15% or more. Read the full paper at nejm.org/doi/full/10.1056/NEJMoa2032183.

The STEP-1 numbers are the cleanest benchmark for what semaglutide can do for weight loss at its maximum dose. They apply to Wegovy, not to Ozempic.

Ozempic at 2.0 mg: a smaller weight loss

Ozempic’s dose ceiling for diabetes is 2.0 mg per week. The diabetes-population SUSTAIN trials of semaglutide consistently showed weight loss in the 4 to 6 kilogram range (approximately 4 to 6% of starting body weight) at 52 to 68 weeks, lower than the STEP-1 weight loss because the dose is lower and the trial populations were different. For patients using Ozempic off-label for weight loss without diabetes, real-world weight loss tends to fall between the SUSTAIN diabetes data and the STEP-1 obesity data, depending on dose tolerated and adherence.

SURMOUNT-1: tirzepatide 15 mg

The SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, enrolled 2,539 adults with overweight or obesity and randomized them to tirzepatide 5 mg, 10 mg, 15 mg, or placebo for 72 weeks. Mean body weight reductions were 15.0% on 5 mg, 19.5% on 10 mg, and 20.9% on 15 mg, compared with 3.1% on placebo. Approximately 57% of participants at the highest dose lost 20% or more of body weight. Read the full paper at nejm.org/doi/full/10.1056/NEJMoa2206038.

SURMOUNT-5: the head-to-head

SURMOUNT-5 is the first direct head-to-head comparison of tirzepatide 15 mg and semaglutide 2.4 mg. The trial enrolled 751 adults with obesity (without type 2 diabetes) and reported that tirzepatide produced 47% greater relative weight loss than semaglutide at 72 weeks. The trial was conducted by Eli Lilly and reported in 2024; further peer-reviewed analyses are emerging through 2026.

What that means in plain terms

• If you compare tirzepatide 15 mg to Ozempic 2 mg, the average difference in body weight reduction is roughly 15 percentage points (about 21% versus about 6%).
• If you compare tirzepatide 15 mg to Wegovy 2.4 mg, the average difference narrows to about 5 to 6 percentage points (about 21% versus about 15%).
• Either way, tirzepatide comes out higher on average. The advantage is largest when Ozempic is on the other side, because Ozempic was not dosed for maximum weight loss.

[STAT BAR: Tirzepatide 15 mg (SURMOUNT-1) | 20.9% | 95%] [STAT BAR: Wegovy 2.4 mg (STEP-1) | 14.9% | 68%] [STAT BAR: Ozempic 2 mg (SUSTAIN program) | ~6% | 27%] [STAT BAR: Placebo (STEP-1) | 2.4% | 11%]

Visual card title: “Visual: average weight loss in trials.” Caption: Mean percentage body weight reduction at trial endpoint.

Tirzepatide and Ozempic share a gastrointestinal-dominant side effect profile because the mechanism that slows gastric emptying is also the one that causes nausea. The differences between the two come down to magnitude and timing.

Most common side effects, by registration trial rates

• Nausea - 43.9% on semaglutide 2.4 mg (Wegovy) versus 33.3% on tirzepatide 15 mg (Zepbound). Ozempic’s diabetes trials reported nausea in 11 to 20% of patients depending on dose.
• Diarrhea - 30.0% on semaglutide 2.4 mg versus 22.0% on tirzepatide 15 mg.
• Vomiting - 24.1% on semaglutide 2.4 mg versus 19.0% on tirzepatide 15 mg.
• Constipation - 24.2% on semaglutide 2.4 mg versus 17.0% on tirzepatide 15 mg.

The lower side-effect rates on tirzepatide in head-to-head comparison are likely a function of its longer titration schedule (six dose steps over six months) rather than a fundamental tolerability difference. Patients on Ozempic specifically often report milder side effects than the Wegovy numbers above because Ozempic’s maximum dose is lower.

Serious adverse events

Both medications carry a boxed warning for the risk of thyroid C-cell tumors observed in rodent studies. Risk in humans has not been established. Both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Pancreatitis and gallbladder disease are uncommon but documented adverse events for both. In SURMOUNT-1, serious adverse events occurred in 6.3% of tirzepatide recipients versus 6.7% on placebo; in STEP-1, in 9.8% of semaglutide recipients versus 6.4% on placebo.

What changes when you escalate the dose

For both drugs, nausea is most pronounced during the four weeks after a dose increase and tapers down. Patients who titrate slowly, eat smaller meals, and prioritize protein and hydration usually find side effects manageable. At Harbor, clinicians often pause a dose escalation or split the next step in half if nausea is severe enough to disrupt daily life. See our guide on managing tirzepatide side effects for the specific symptom-by-symptom playbook the Harbor team uses.

The cost picture has three layers worth understanding: brand-name list prices, real out-of-pocket after insurance or savings programs, and compounded options.

Brand-name list prices

• Ozempic - approximately $968 per month list price.
• Wegovy - approximately $1,349 per month list price.
• Mounjaro - approximately $1,069 per month list price.
• Zepbound - approximately $1,059 per month list price for autoinjector pens. Eli Lilly’s self-pay program for Zepbound vials offers single-dose vials at approximately $499 per month for the 5 mg and below doses.

Insurance coverage

Coverage of GLP-1s for weight management remains the largest single barrier to access in 2026. Commercial plans cover Wegovy and Zepbound for weight management at variable rates with prior authorization. Medicare Part D was directed to begin covering Wegovy in 2024 for patients with established cardiovascular disease, and Zepbound for obstructive sleep apnea coverage followed. Most state Medicaid programs do not cover GLP-1s for weight loss. Ozempic and Mounjaro for diabetes are widely covered with prior authorization. The Centers for Medicare and Medicaid Services maintains current Part D guidance at cms.gov.

Compounded preparations

Compounded semaglutide and tirzepatide became widely available during the 2022 to 2024 FDA shortage period under 503A pharmacy oversight. As branded supply has improved, the regulatory environment has tightened. Compounded preparations remain legal under specific shortage and clinical-need conditions, and licensed 503A pharmacies continue to dispense them with physician oversight. Pricing ranges from approximately $150 to $400 per month depending on dose and provider.

At Harbor, members access compounded semaglutide at $99 per month and compounded tirzepatide at $149 per month, both with the 12-month results guarantee, 24/7 clinician access, and on-time refill protection. We compare Harbor side-by-side with other GLP-1 programs on our compare page.

Switching from Ozempic to tirzepatide is one of the most common transitions Harbor’s clinical team manages. Patients typically switch for one of three reasons: results have plateaued on Ozempic, side effects on Ozempic are intolerable, or a clinician believes the dual mechanism is a better fit for the patient’s goals.

The standard clinical protocol

1. Take the last Ozempic dose. Both drugs are weekly injections, so the protocol uses the standard one-week interval.
2. Wait one week. One week clears the prior semaglutide dose to a level where it no longer contributes meaningfully to side effects or hypoglycemia risk.
3. Start tirzepatide at the 2.5 mg starting dose. Even if a patient was on a higher semaglutide dose like 2.0 mg, the standard restart is at 2.5 mg per the Zepbound and Mounjaro labels. This minimizes initial GI side effects.
4. Titrate every four weeks. The standard escalation is 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, with the option to hold at any step if the response is adequate or side effects are limiting.
5. Adjust co-medications. Patients on insulin or sulfonylureas need careful glycemic monitoring during the switch to avoid hypoglycemia.

What to expect during the switch

Weight loss typically pauses or slows for the first one to two weeks after the switch and then reaccelerates once tirzepatide reaches an effective dose. Side effects often recur briefly during the first dose escalation because the body is re-introduced to a low circulating drug level. Most members report side effects equal to or milder than what they experienced when they first started Ozempic, because tirzepatide’s titration is gradual.

Harbor’s clinicians manage all medication switches through the patient portal. The 12-month results guarantee applies across the switch, and dietitian access in the maintenance phase carries forward. For a deeper walk-through, see our decision framework on choosing a GLP-1 medication.

The honest answer is that both medications are reasonable choices for most patients with overweight or obesity. The differences are at the margin, and the margin is where Harbor’s clinical team matches a member to one or the other.

Tirzepatide is usually the right call when

• You have a goal of losing 20% or more of your starting body weight.
• Your starting BMI is 35 or higher.
• You have tried semaglutide (Ozempic or Wegovy or compounded) and plateaued before reaching your goal.
• You have insulin resistance or type 2 diabetes co-existing with overweight or obesity. Tirzepatide tends to produce stronger A1C reductions than semaglutide at comparable doses.
• You have obstructive sleep apnea associated with obesity (Zepbound is now FDA-approved for this indication).

Ozempic (or more accurately, semaglutide) is usually the right call when

• You have type 2 diabetes and Ozempic specifically is the right brand for you (insurance coverage, on-label use, cardiovascular benefit in established heart disease).
• You want weight loss in the 10 to 15% range and have a starting BMI in the 27 to 35 range.
• Cost-sensitivity is a major factor and Wegovy is not covered. Compounded semaglutide through Harbor at $99 per month is the lowest-cost path to a clinically meaningful weight loss.
• You want the longer post-market safety record. Semaglutide has been on the US market since 2017; tirzepatide since 2022.
• You have a history of significant nausea or GI sensitivity on prior GLP-1 attempts (tirzepatide’s larger top dose can be harder to tolerate for some).

When neither is the right starting point

For severe obesity (BMI 40 or higher, or BMI 35 with comorbidities) where the weight-loss target exceeds what GLP-1 therapy alone can deliver, bariatric surgery remains the standard of care and produces greater long-term weight loss than either medication. GLP-1 therapy can serve as a bridge to surgery, an adjunct after surgery, or an alternative for patients unwilling or unable to undergo surgery. Harbor’s clinical team will refer when bariatric surgery is the better clinical fit.

Most weight-loss programs frame “tirzepatide vs Ozempic” as a forever choice. We treat it as a starting point. About 60% of new Harbor members start on compounded semaglutide and about 40% start on compounded tirzepatide, matched to their starting BMI, weight-loss goal, prior GLP-1 history, side-effect tolerance, and cost preferences. One in five members who start on semaglutide eventually switches to tirzepatide because of plateau or insufficient efficacy. The switch is managed through the patient portal without a price increase.

The medication is one part of what Harbor provides. The other parts are the structural pieces that prevent rebound: 24/7 access to a board-certified clinician through the patient portal, on-time refill guarantee so no member runs out, dietitian access in the maintenance phase after the medication ends, and a 12-month results guarantee. The goal is reaching a goal weight and staying there, not staying on medication forever. Read more about the science behind how GLP-1s work and how Harbor compares to other programs.